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Introduction
Coumadin is a commonly used blood thinner worldwide that consists of a 1:1 mixture of Rand S-warfarin (Figure 1 ) (Ansell et al., 2008) . The anticoagulant effect of warfarin reflects inhibition of VKORC, which plays a critical role in vitamin K cycling and the maturation of coagulation factors. Though very efficacious, warfarin can be difficult to optimally treat patients due to its narrow therapeutic range and inter-individual variations in response. Doses have to be individually established for each patient based on how they respond to the medication. Failure to achieve and maintain an optimal dose for patients increases risks for potentially lifethreatening adverse events due to under dosing (strokes) and over dosing (bleeding) (Wysowski et al., 2007) . Knowledge of the causes of this variability in dose-responses can then lead to better management strategies.
Inter-individual variations in patient dose-responses to warfarin often reflect the importance of drug metabolism (Jones and Miller, 2011) . Cytochromes P450 oxidize R-and S-warfarin into hydroxywarfarins, and as major routes for drug clearance, those metabolic pathways have dominated the focus of most studies. Through minor, less characterized pathways, both drugs also undergo reduction at the carbonyl at position 11 to yield warfarin alcohols. Warfarin reduction introduces a second chiral center, making two of warfarin alcohol diastereomers for each warfarin enantiomer. For R-warfarin, the two metabolites are 9R,11R-or 9R,11S-warfarin alcohol (RR-or RS-warfarin alcohol), and for S-warfarin, they are 9S, . Warfarin alcohols retain pharmacological activity that is 6-fold lower than that for the parent drugs (Gebauer, 2007) ; however, clearance of RS-warfarin alcohol is 2.5-fold lower than the other alcohols indicating selective accumulation of the metabolite in plasma based on stereochemistry (Lewis, 1973) , which increases their relative potency during maintenance dosing (Haque et al., 2014) . According to a previous report (Haque et al., 2014) , warfarin alcohols are the most potent of the warfarin metabolites, This article has not been copyedited and formatted. The final version may differ from this version. Recent studies using subcellular fractions from rats (Alshogran et al., 2015a) and humans (Malátková et al., 2016) have provided limited insights on reductive pathways for warfarin due to reliance on rac-warfarin and not the actual drug enantiomers as a substrate and the subsequent lack of chiral resolution of metabolites from the reaction. First, the drug is administered as a 1:1 mixture of enantiomers, but those conditions do not reflect patient serum levels and mask actual clearance of individual warfarin enantiomers. Reported R-warfarin levels in patients are on average two-fold higher than S-warfarin Jones et al., 2010; Haque et al., 2014) . Knowledge of the metabolic kinetics for individual drug enantiomers would provide perspective for assessing their relative significance in drug clearance. Moreover, the use of a mixture of substrates in those studies masks possible drug-drug interactions between the enantiomers, which were implicated in one of the studies (Malátková et al., 2016) . Second, it is not possible to extrapolate the metabolic kinetics for R-and S-warfarin from those for racwarfarin so that knowledge of the impact of stereochemistry on metabolic clearance of the drugs remains unknown. Third, current studies on warfarin reduction failed to resolve all four diastereomers generated during rac-warfarin reduction. Instead, reported kinetic parameters reflect the formation of mixtures of metabolites, i.e. alcohol 1 (RR-and SS-warfarin alcohols) and alcohol 2 (RS-and SR-warfarin alcohols), generated during rac-warfarin metabolism, and hence provide no information on the kinetics for individual pathways leading to specific metabolites. Taken together, the current findings provide only a qualitative perspective on warfarin reduction and lack specific quantitative details on the individual pathways that would determine their potential clinical relevance. Herein, we report the impact of stereochemistry on the efficiency of rac-, R-, and S-warfarin reduction by pooled human liver cytosolic (HLC150) cell fractions. Due to the lack of commercially available standards, we synthesized and purified all four diastereomeric warfarin alcohols using green chemistry techniques. We then optimized reaction conditions to achieve steady state conditions and carried out kinetic studies with R-and S-warfarin along with racwarfarin for comparison to findings from other studies. We assessed potential interactions between the drug enantiomers by simulating rac-warfarin metabolism using parameters for the individual drugs and compared them to those measured for rac-warfarin in our study and kinetic values reported in the literature that used a limited pool of cytosol fraction from five cadavers (Malátková et al., 2016) . Lastly, we employed inhibitor phenotyping to identify possible reductases responsible for warfarin metabolism in cytosolic fractions.
Materials and Methods
Materials. HPLC grade methanol, acetic acid, dimethyl sulfoxide (DMSO), and NADPH were purchased from Thermo Fisher (Pittsburgh, PA) and pooled human liver cytosol (HLC150) from BD Biosciences. Diethyl ether, hydrochloric acid, ethyl acetate, acetone, and acetic acid were obtained from PHARMCO-AAPER (Brookfield, CT). Sodium borohydride and DMS0-d 6 was purchased from Sigma-Aldrich (St. Louis, MO). Rac-Warfarin, warfarin alcohol mixed isomers, and hydroxywarfarins (internal standards) were obtained from Toronto Research Chemicals (Toronto, Canada). Individual R-and S-warfarin stereoisomers were prepared in a previous study(Preston Pugh et al., 2014) , while the metabolites 9R,11R-; 9R,11S-; 9S,11R-; and 9S,11S-warfarin alcohols were synthesized and purified to >98% purity.
Synthesis of warfarin alcohols through green chemistry.
We prepared authentic isomers of all four diastereomeric warfarin alcohols by synthesizing R-and S-warfarin and then reducing them individually followed by isolating the individual alcohols by thin layer chromatography and cycles of recrystallization. First, R-and S-warfarin were prepared with greater than 99% This article has not been copyedited and formatted. The final version may differ from this version. enantiomeric excess using a green chemistry procedure as described by us (Preston Pugh et al., 2014) and others (Kim et al., 2006; Wong et al., 2010) . Second, reduction of R-and Swarfarin to warfarin alcohols followed a literature procedure (Trager, 1970; Chan et al., 1972 ).
The R-or S-warfarin (50 mg, 1.62 mmol) was stirred in one mL of deionized water with sodium borohydride (7 mg, 1.85 mmol) at the ambient temperature for 2 hr. Excess sodium borohydride was neutralized by addition of one mL of 0.5 M hydrochloric acid added dropwise with stirring.
The mixture was filtered and washed with water. The resulting white solid was allowed to air dry. The reduction step for each warfarin enantiomer introduced a new chiral center resulting in a pair of diastereomers, i.e. RS and RR warfarin alcohols for R-warfarin and the SS-and SRwarfarin alcohols for S-warfarin. The typical yield of each pair of diastereomers was greater than 70%.
Isolation of individual alcohol diasteromers was achieved through silica gel thin layer chromatography (TLC) followed by recrystallization. For example, a diastereomer mixture of two warfarin alcohols (either RS and RR, or SR and SS) was dissolved in the smallest amount of ethyl acetate and dropped onto a Sorbtech Silica XHL TLC plate W/UV254 (glass backed, 250 µm thickness, 20 x 20 cm dimensions). A solvent mix of 197:3 diethyl ether:acetic acid was used to effect a separation. The bottom bands of each separation were the RR-and SSwarfarin alcohols, while the top bands were the RS and SR-warfarin alcohols. TLC identity of the aforementioned diastereomers was based upon the previous research by others (Supplemental Data, (Chan et al., 1972) ). Each band was carefully scraped from the glass TLC plate and ethyl acetate was added to dissolve the alcohols. After stirring, the mixture was filtered over Celite and ethyl acetate was removed by rotary evaporation. The white solid was dissolved in the smallest amount of warm acetone, and then drops of warm water were added slowly until the solution remained cloudy. At this point the solution was heated again until clear and allowed to cool at the ambient temperature until crystals appeared, at which point the This article has not been copyedited and formatted. The final version may differ from this version. 124.4 (C-5), 125.1 (C-6), 127 (C-4'), 128.9 (C-3'), 129 (C-2'), 132.9 (C-7), 144.7 (C-1'), 154 (C-9), 164 (C-4), 164.9 (C-2).
Identification of initial rate conditions for warfarin reduction. Prior to steady-state studies,
control experiments with HLC150 were carried out to determine optimal co-solvents, reaction buffers, reaction time, and protein concentration to ensure steady-state conditions and avoid confounding effects from experimental reagents. Warfarin stocks were prepared in methanol were carried out using rac-warfarin and experimental effects monitored by measuring total product formation by combining areas of alcohols 1 and 2 to take all four alcohol diastereomers into account. All control reactions were carried out in duplicate.
Analysis of warfarin reduction by HPLC. The resolution and quantitation of individual drugs
and metabolites was achieved through high performance liquid chromatography (HPLC).
Samples were injected onto a Waters HPLC Breeze system equipped with a 4.6 x 150 mm Zorbax Eclipse 3.5 µM XDB-C18 column (Agilent) heated to 45°C and analytes were resolved Inhibitor phenotyping of R-and S-warfarin reduction. HLC150 phenotyping reactions were carried out using the steady state conditions established in the control experiments (see Results) . We prepared all inhibitor stocks in methanol and assessed their effects against a control reaction containing just methanol at the same final percent (5% methanol). R-or SWarfarin concentrations at 50 and 500 µM were used in the presence of three different inhibitors to selectively inhibit individual and classes of cytosolic reductases (as reviewed in (Malátková and Wsól, 2014) ). Moreover, with broadly specific inhibitors, we employed concentrations about 5-fold above the reported IC 50 to ensure target inhibition while minimizing off target effects. We used 2 µM flufenamic acid (FFA), which inhibits all Aldo-keto Reductase family 1C members (AKR1C). This concentration has also been shown to inhibit AKR1B10 activity (Zhang et al., 2013) ; however, levels are typically too low to be relevant for our studies, and induction was observed only in liver cancer (Laffin and Petrash, 2012) . For indomethacin (IND), a high concentration (180 µM) would similarly inhibit all AKR1C members and Carbonyl Reductase 1 (CBR1), while a lower concentration (5 µM) has a more selective effect on AKR1C3 with only limited CBR1 inhibition expected. We targeted Carbonyl Reductase 1 (CBR1) activity for inhibition using 60 µM quercetin. In addition, we combined inhibitors to assess the collective contributions of AKR1C and CBR1 enzymes. AKR1B1 is also inhibited by indomethacin and quercetin (Byrns and Penning, 2009) , but this enzyme is only expressed at minimal levels in the liver, except in cases of alcoholic liver disease (O'CONNOR et al., 1999) . Thus, we do not expect it to significantly contribute to metabolism in our study.
Results
This article has not been copyedited and formatted. The final version may differ from this version. Figure 2 .
Warfarin reduction was more efficient in potassium phosphate over Tris-HCl buffer, and MgCl 2 had no impact on reaction rates (Panel A). Variations in methanol co-solvent levels had no effect on activity while higher DMSO levels inhibited the reaction (Panel B). Observed warfarin alcohol levels increased essentially linearly with total protein concentration (Panel C). Over the course of 60 min, product formation levels were essentially linear (Panel D). Based on these studies, the standard conditions for a 30 min reaction with 0.25 mg/mL protein was 50 mM potassium phosphate 7.4, no MgCl 2 , and 1% methanol as a co-solvent.
Stereospecificity played a significant role in the steady state reduction of warfarin enantiomers and corresponding products from cytosolic reactions ( Figure 3 , Table 1 ). The Rwarfarin reactions yielded RS-warfarin alcohol as the major metabolite and RR-warfarin alcohol as the minor one. Both reactions were best fit to a simple Michaelis-Menten kinetic model as compared to a non-hyperbolic curve described by the Hill equation. The metabolic efficiency for formation of the RS-warfarin alcohol was nearly 200-fold compared to the RR-warfarin alcohol due almost exclusively the difference in rate of the reaction. Similarly, the reduction of Swarfarin yielded the analogous metabolites, i.e. SS-warfarin alcohol and SR-warfarin alcohol.
The kinetic profile for SS-warfarin alcohol was fit to the Michaelis-Menten model, yet the predicted K m was greater than the highest substrate concentration used in this study (1000 µM) due to solubility limits. Thus, there is more error in the kinetic constants than predicted by a fit, hence the exclusion of standard error from the Table. The SR-warfarin alcohol was consistently measurable but remained at the limit of quantitation so that it was not possible to determine the kinetics for its formation. Taken together, the rate of S-warfarin conversion to SS-warfarin alcohol was about 9-fold lower than that for R-warfarin to RS-warfarin alcohol at 1000 µM, indicating a strong preference for R-warfarin reduction and formation of S alcohols regardless of substrate chirality.
In addition, we followed the experimental design reported by others (Alshogran et al., 2015a; Malátková et al., 2016) to carry out steady-state studies with rac-warfarin for comparative purposes. Unlike the previous experiments in this study, substrate concentration reflected an initial 1:1 mixture of R-and S-warfarin, and the corresponding diasteromeric metabolites were not resolved completely. We used the previously reported nomenclature (Alshogran et al., 2015a; Malátková et al., 2016) Table 1 ). The lack of resolution of the substrates or metabolites with this approach made it impossible to identify the actual major and minor metabolites for R-and S-warfarin without relying on our initial enantiospecific steady-state kinetic studies.
Inhibitor phenotyping of cytosolic enzymes responsible for R-and S-warfarin reduction.
General and relatively specific reductase inhibitors indicated multiple enzymes likely contribute to overall reduction of R-and S-warfarin in the cytosol. The overall patterns of inhibition were similar between the formation of the corresponding major metabolites RS-warfarin alcohol and SS-warfarin alcohol ( Figure 5 ). The minor metabolites RR-warfarin alcohol and SR-warfarin alcohol were measured at levels too low for quantitative kinetics. Substrate concentrations had little effect on the patterns of inhibition for the compounds with two exceptions. First, the effect of quercetin inhibition was consistently significant but reduced for S-warfarin under low substrate conditions. Second, inhibition by low indomethacin concentration (5 µM) was reduced at lower concentration for both warfarin enantiomers. By 180 µM indomethacin, all reduction rates were decreased greater than 10-fold. These findings suggest a dominant role for AKR1C3
This article has not been copyedited and formatted. The final version may differ from this version. and SS-warfarin alcohols. Addition of 5 µM indomethacin to the quercetin reaction did not significantly impact the observed reduction rates; however by180 µM indomethacin there was a further approximate 10% decrease in rates. Unlike indomethacin, flufenamic acid had little effect on reduction, despite both being previously shown to inhibit AKR1C family enzymes (Malátková and Wsól, 2014) . This difference could be due to variability in AKR1C inhibition by flufenamic acid depending on the substrate being metabolized, as shown in previous studies (Malátková and Wsól, 2014) . Overall, these results suggest that AKR1C family enzymes and CBR1 participate in the reduction of R-and S-warfarin.
Discussion
Herein, we demonstrated that stereospecificity played an important role in the efficiency of warfarin reduction and the corresponding metabolites generated in the process. This metabolic pathway is low affinity and high capacity, although it is likely underutilized under in vivo conditions. These insights from the kinetics differ from previous reports relying on rac-warfarin and a failure to resolve parent drugs and their metabolites in the analyses. We replicated the findings of others and demonstrated how the experimental design confounds an accurate understanding of R-and S-warfarin reduction. Our subsequent phenotyping studies revealed the probable cytosolic reductases responsible for stereospecific metabolism of warfarin.
Collectively, these findings provide a strong foundation for further studies, such as genotyping of reductases, to explore the clinical relevance of R-and S-warfarin in patients undergoing anticoagulant therapy.
Our data show that human cytosolic reductases more efficiently metabolized R-warfarin over S-warfarin and preferentially generate S alcohols in the process, which is consistent with previous studies involving both humans and animal models Hermans and This article has not been copyedited and formatted. The final version may differ from this version. Thijssen, 1992). According to our kinetics, warfarin reduction is a low affinity but high capacity metabolic pathway that is likely underutilized under in vivo conditions. Maintenance dosing to achieve a targeted therapeutic response results in low micromolar levels of R-and S-warfarin in plasma (1518 to 4500 nM as compiled in (Haque et al., 2014) ). The amounts accessible for reduction are likely about 50-fold lower (mid-nanomolar range) due to high plasma protein binding (O'Reilly, 1986) . A possible limitation of this estimation is the lack of consideration of warfarin accumulation in the liver. Studies with rats have shown liver warfarin levels are possibly three-fold higher than that observed in plasma (Levy et al., 2003; Sun et al., 2015) .
The similarities in physiology between rats and humans suggest that warfarin accumulation in liver is possibly occurring in humans. Even taking this effect into consideration, in vivo levels of R-and S-warfarin would not approach saturation, so that their reductive elimination would present as essentially linear kinetics in patients.
Steady-state reduction of rac-warfarin by human liver cytosol yielded similar results to that reported by others (Moreland and Hewick, 1975; Alshogran et al., 2015b; Malátková et al., 2016 ), yet we were able to provide a more in-depth analysis of the data given our kinetics for the individual drug enantiomers. Despite the use of different human liver cytosolic fractions, warfarin alcohol 2 was the major metabolite while warfarin alcohol 1 was the minor one. The V max and K m values for the alcohol 2 reaction were nearly identical between the studies, as shown in Table 1 . The corresponding values for alcohol 1 were within two-fold of one another; that difference could be due to error in the noise in data for the minor pathway. In our case, we can identify likely metabolites contributing to observed kinetic profiles for warfarin alcohols 1 and 2. The RS-warfarin alcohol is the primary contributor to the alcohol 2 and SS-warfarin alcohol to the alcohol 1. SR-and RR-Warfarin alcohols would still contribute to observed mixtures of alcohols as metabolites of the reaction, such that the observed kinetics for rac-warfarin do not represent that for the individual warfarin enantiomers.
This article has not been copyedited and formatted. The final version may differ from this version. Based on the identification of the metabolites, we assessed potential interactions between the warfarin enantiomers that could occur when rac-warfarin served as a substrate. For comparative purposes, we predicted the apparent alcohol 1 and 2 formation rates for racwarfarin if the R-and S-warfarin did not interact. Under those conditions, observed rates would simply be the summation of the corresponding rates for metabolites contributing to alcohol 1 (RR-and SS-warfarin alcohols) and alcohol 2 (RS-and SR-warfarin alcohols) taken from our steady-state data for the reactions with the individual drug enantiomers. As shown in Figure 6 , the predicted formation rates for warfarin alcohols from rac-warfarin were calculated by summing individual warfarin alcohol rates from warfarin enantiomers as described previously.
The predicted kinetic profiles significantly differ from the experimentally measured values as shown by the dashed lines versus the solid lines. When both drug enantiomers are present, the apparent V max and K m are lower indicating R-and S-warfarin interact to impact their reduction to the corresponding alcohols, as has been suggested previously (Chan et al., 1972) .
Nevertheless, the quantitation of mixtures of the alcohol metabolites precludes the ability to identify the mechanism of interaction and thus understand its impact on major and minor pathways for R-and S-warfarin reduction. These findings further underscore the complications for relying on rac-warfarin metabolic kinetics to understand its relevance to human metabolism of the drug.
The inhibitor phenotyping indicated that AKR1C3 and CBR1 dominated reductive metabolism of R-and S-warfarin in the cytosol, while AKR1C1/2 may have made minor contributions. These major enzymes shared similar preference for R-warfarin over S-warfarin as a substrate and generated S alcohols regardless of substrate chirality. This stereospecificity for the cytosolic reductases results in the overall preference formation of the major RS-warfarin metabolite followed by the minor SS-warfarin metabolite with trace levels of the other warfarin alcohols. Carbonyl reducing enzymes demonstrate stereospecificity that depends on substrate and the particular enzyme (Hoffmann and Maser, 2007) . CBR1 substrates range in molecular mass from 207 g/mol for 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) to 543 g/mol for doxorubicin (Malatkova et al., 2010) , which includes the mass of warfarin (308 g/mol). The enantiospecificity of these reactions has only been reported for NNK in which there is a more than 90% preferential formation of the S-alcohol (Breyer-Pfaff et al., 2004) , as observed for Rand S-warfarin reduction in this study. Nevertheless, stereospecificity does vary among individual members of the AKR1C family (Rižner and Penning, 2014) .
As further evidence for their role in R-and S-warfarin metabolism, recombinant AKR1C3
and CBR1 readily catalyzed the reduction of rac-warfarin compared to AKR1B1, 1C1, 1C2, and 1C4 along with CBR3 (Malátková et al., 2016) ; however, the use of a mixture of R-and Swarfarin and lack of resolution of substrates and metabolites obscured the stereospecificity of substrate recognition and metabolite formation by the reductases. When considered with respect to our observations, the importance and consequence of AKR1C3 and CBR1 in R-and S-warfarin becomes more clearly the cause for preferential metabolism of R-warfarin and formation of its RS-warfarin alcohol metabolite as major reductive pathways in humans.
Concluding Remarks. The kinetics for R-and S-warfarin metabolism by these reductases could impact clearance of the parent drugs and formation of pharmacologically active metabolites in patients undergoing anticoagulant therapy. For the average patient, R-warfarin will primarily undergo reduction compared to S-warfarin and thus impact its contributions to anticoagulation as well as the resulting less pharmacologically active warfarin alcohol metabolites (Lewis, 1973) . The relevance of warfarin reduction on patient dose response variability will depend on genetics, personal habits, and environmental factors that influence reductase activity (Kassner et al., 2008) . Xenobiotics including drugs and pollutants interact with aryl hydrocarbon receptor (AhR) to bind to xenobiotic response elements (XRE) that regulate expression and activity of drug metabolizing enzymes including CBR1 (Lakhman et This article has not been copyedited and formatted. The final version may differ from this version. , 2007) . By contrast, AKR1C are likely regulated through antioxidant regulatory pathways (Burczynski et al., 1999) stimulated by habits suggest as smoking, which induces AKR1C3 levels 15-fold (Nagaraj et al., 2006) . That effect could explain why smokers are resistant to warfarin anticoagulation by increasing drug metabolism. Similarly, genetic variants of AKR1C3 (Mindnich and Penning, 2009 ) and CBR1 (Malatkova et al., 2010) would increase or decrease their roles in warfarin metabolism and hence patient responses, so if shown relevant, the polymorphisms could be incorporated into current pharmacogenetic-based dosing algorithms (Shaw et al., 2015) to improve their predictability. Aside from those unexplored possibilities, the relative contribution of warfarin reduction to the more dominant oxidative pathways remains unknown so that their collective effect on R-and S-warfarin metabolism requires further investigation. In sum, knowledge of the stereospecificity and efficiency of warfarin reduction provides a critical advance in understanding the overall relevance of metabolism that could impact patient dose-responses.
This article has not been copyedited and formatted. The final version may differ from this version. Reaction activities were normalized to the average control rate measured for reactions in the absence of inhibition. Rates were reported as percentages of the control rate. The reported activities are averaged from a minimum of five individual experiments ± standard error.
Asterisks indicate statistical significance of inhibition compared to control as calculated using Student's t-test (* p<0.05, ** p<0.005; *** p < 0.0005). Tables  Table 1 -Steady state kinetic constants for R-, and S-, and rac-warfarin reduction by human liver cytosol a Best fit of data was determined between hyperbolic (Michealis-Menten) and non-hyperbolic (Hill equation) models using extra sum-of-squares F-test in GraphPad Prism.
b SR-Warfarin alcohol was consistently quantifiable only at S-warfarin concentrations of 600 µM or greater, yet data could not be reliable fit to any kinetic model. The predicted Km was greater than the highest substrate concentration used in this study (1000 µM) due to solubility limits, and thus, there is more error in the kinetic constants than predicted by a fit hence the exclusion of standard error from the Table. 
